Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoVAC-1 Vaccine in B-cell/Antibody Deficient Adults
NCT04954469Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CoVac-1 in coronavirus disease 2019 (COVID-19), sponsored by University Hospital Tübingen. Primary endpoints: Safety-Vital Signs 1 (Body Temperature) at Day 28, Safety-Vital Signs 2 (Blood Pressure and Pulse) at Day 28 and 6 more. Started Jun 2021; status: completed.
02
Drugs
CoVac-1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04954469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04954469.